STRATEGYPPLadmin2022-02-15T00:59:35+00:00
The strategic objective of the company is to partner with appropriate market leader(s) that have the resources to maximize the market potential of the Phoenix compounds. Several leading pharma companies that have a strategic focus on pain have indicated interest in partnering by the end of Phase 1. We plan to advance PPL-138 into Phase 1 clinical trials in 2022-2023, and position it for optimal deal terms, ideally by 2024. Phoenix will then use a portion of license fee proceeds to advance PPL-103 for addiction therapy and for pain into Phase 1 clinical trials and continuing to continue to Proof of Concept. Phoenix plans to register the Company as publicly-traded in the next few years so that investors may choose to realize the future values of cash flows.